Alan F. Denenberg

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NanoString Technologies, Inc. of $230 million aggregate principal amount of its 2.625% convertible…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NuVasive, Inc. of $450 million aggregate principal amount of its 0.375% convertible senior notes due…

Davis Polk advised the sales agent in connection with the SEC-registered at-the-market offering by CytomX Therapeutics, Inc. of its common stock for up to an aggregate amount of $75 million…

Davis Polk advised the underwriters in connection with an SEC-registered offering by Citrix Systems, Inc. of $750 million aggregate principal amount of its 3.300% senior notes due 2030…

Davis Polk advised the underwriters in connection with an initial public offering of 16,100,000 shares of common stock of Revolution Medicines, Inc. at $17.00 per share (which includes the…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Revance Therapeutics, Inc. of $287.5 million aggregate principal amount of its 1.75% convertible senior…

Davis Polk advised Shockwave Medical, Inc. in connection with a $16.5 million supplemental term loan provided by Silicon Valley Bank. Shockwave Medical used a portion of the proceeds…

Davis Polk advised the underwriters in connection with the $148.5 million public offering of ordinary shares by Theravance Biopharma, Inc. Theravance Biopharma’s ordinary shares…

Davis Polk advised the joint book-running managers in connection with a $2.25 billion SEC-registered debt offering by Intel Corporation. The offering consisted of $750 million…

Davis Polk advised SMART Global Holdings, Inc. in connection with a Rule 144A offering of $250 million aggregate principal amount of its 2.25% convertible senior notes due 2026. Davis Polk…